ArticleCase reports in oncology
Metastatic Renal Cell Carcinoma with Concomitant Minimal Change Disease: Enabling Immunotherapy with Rituximab - A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) have transformed the treatment of metastatic renal cell carcinoma (RCC). Their use in patients with preexisting autoimmune diseases is challenging due to the risk of flares and the impact of baseline immunosuppression on treatment effectiveness. Minimal change disease (MCD), an immune-mediated glomerulopathy usually managed with corticosteroids and other immunosuppressants, poses a therapeutic challenge for immunotherapy. Case Presentation: We report the case of a 44-year-old man diagnosed with metastatic clear cell RCC with sarcomatoid differentiation, who also had a history of steroid-dependent MCD. To enable immunotherapy, we collaborated with nephrology to adjust the patient's immunosuppressive regimen. The patient was transitioned from prednisone and cyclosporine to rituximab (1 g intravenously on days 1 and 15) as a steroid-sparing strategy. Cabozantinib monotherapy was initiated to address the high tumor burden while immunosuppression was being optimized. Following successful tapering of corticosteroids and discontinuation of the calcineurin inhibitor, nivolumab was subsequently added. The patient developed immune-related hypothyroidism, which was successfully managed with hormone replacement. Restaging imaging demonstrated radiological response, and treatment was continued with good tolerance. Conclusion: This case underscores the importance of multidisciplinary management for patients with cancer and concurrent autoimmune disease. Adjusting baseline immunosuppression with targeted strategies, such as B-cell depletion, may be a practical approach to enable immunotherapy while maintaining control of autoimmune conditions. Careful selection of treatment and personalized therapy may facilitate safe and effective ICI-based treatment in selected patients with metastatic RCC and MCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.